Policy & Regulation
Celgene Posts Results of AUGMENT Evaluating Revlimid In Combination with Rituximab In Patients with Relapsed/Refractory Indolent Lymphoma
6 December 2018 - - US-based biopharmaceutical company Celgene Corp. (NASDAQ: CELG) has presented results of the phase 3 AUGMENT study, which showed that Revlimid (lenalidomide) in combination with rituximab demonstrated superior progression-free survival in patients with relapsed/refractory indolent lymphoma compared to patients who received rituximab plus placebo (R-placebo), the company said.

The data were presented by John Leonard, M.D. in an oral presentation at the 60th American Society of Hematology annual meeting and Exposition in San Diego, C.A.

The phase 3 randomised, double-blind, international clinical study evaluated the efficacy and safety of the investigational combination of R2 versus rituximab plus placebo in patients (n=358) with relapsed/refractory follicular (n=295) and marginal zone lymphoma.

In the study, the R2 arm demonstrated a highly statistically significant improvement in the primary endpoint of progression-free survival, evaluated by an independent review committee, versus the R-placebo arm.

The median PFS was 39.4 months for patients treated with R2 and 14.1 months for those treated with R-placebo (P


Related Headlines